Biodesix Q3 Revenue Misses Estimates by 13% as Net Loss Hits $8 Million
BDSX has more than doubled off its 52-week low of $5.26.
Summary
Biodesix posted Q3 revenue of $24.041 million against an IBES estimate of $27.5 million, a shortfall of roughly 13%, with the company attributing the miss to seasonality impact and project delays. Operating expenses came in at $30.153 million, well above revenue, driving a net loss of $8.032 million for the quarter. The miss matters for a company of this size because the gap to consensus is wide and spending still outruns the top line. The prior timeline only shows insider buying by 10% owner Jack Schuler in August, which does not offset a revenue shortfall.
At the time of this announcement, BDSX was trading at $18.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $209.3M. The 52-week trading range was $5.26 to $31.97. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.